| | | | Effect Measure |
---|
Parameter | Number of Trials | Number of Patients | | MD | SMD | RoM |
---|
Urine Output | 33 | 1654 | Estimate | -- | 0.49 | 1.24 |
| | | 95% CI | -- | 0.29 to 0.69 | 1.14 to 1.35 |
| | | p-value | -- | <0.001 | <0.001 |
| | |
I
2
| -- | 71% | 77% |
Serum Creatinine | 32 | 1807 | Estimate | -3.51 | -0.28 | 0.96 |
| | | 95% CI | -6.71 to -0.23 | -0.51 to -0.06 | 0.93 to 0.99 |
| | | p-value | 0.04 | 0.01 | 0.01 |
| | |
I
2
| 73% | 79% | 73% |
Creatinine Clearance | 22 | 1077 | Estimate | -- | 0.10 | 1.06 |
| | | 95% CI | -- | -0.02 to 0.22 | 1.01 to 1.11 |
| | | p-value | -- | 0.10 | 0.02 |
| | |
I
2
| -- | 0% | 0% |
- The pooled effect measure results are presented along with their 95% confidence intervals and null hypothesis p-values for each of the three renal physiological variables evaluated in the meta-analysis, urine output, serum creatinine, and creatinine clearance, 1 day after the start of therapy. The degree of heterogeneity, expressed using the I
2 statistic for each of the pooled effect measures for each of the variables is also shown. For urine output and creatinine clearance, MD could not be used because units differed across studies. In contrast, all serum creatinine values were expressed as or could be converted to identical units (μmol/L), allowing this variable to also be analyzed using MD.
- Abbreviations: CI – confidence interval, I
2 – I
2 heterogeneity statistic, MD – mean difference, RoM – ratio of means, SMD – standardized mean difference